A note from our CEO, Rohan Greenland – March
16 March 2021
MS Australia CEO, Rohan Greenland, provides an overview on his first two months in the job and the organisations focus for the remainder of 2021.
MS Australia CEO, Rohan Greenland, provides an overview on his first two months in the job and the organisations focus for the remainder of 2021.
New research into myelin repair in MS has found that switching off a gene can improve myelin replacement in laboratory models of MS.
A new medication for relapsing MS has been approved by the TGA in Australia. Ofatumumab will be marketed under the trade name Kesimpta.
The Australian Government has announced the listing of ozanimod (Zeposia) for the treatment of relapsing remitting MS on the Pharmaceutical Benefits Scheme.
By leaving a gift in her Will to MS Research Australia, Pearl is changing the world for people with MS. Read more to find out how you can leave a gift.
In this article we try to break down some of the basics on the COVID-19 vaccination and how it will affect people with MS.
Updates from the International Progressive MS Alliance highlight progress and strategic plans to advance effective treatments for progressive MS.
New research funded by MS Research Australia explores the possibility of childhood dietary intake being associated with developing MS as an adult.
The Pharmaceutical Benefits Advisory Committee will meet in March to discuss the inclusion of ofatumumab on the Pharmaceutical Benefits Scheme.